In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Cardiac rehabilitation: Relevant but undervalued

ESC Congress News 2019 - Paris, France

With the emergence of new and effective secondary prevention pharmacological agents, is there still a place for cardiac rehabilitation?

Cardiovascular Rehabilitation


Prof. Paul DendaleProfessor Paul Dendale (Jessa Hospital, Hasselt, Belgium), President of the European Association of Preventive Cardiology (EAPC) and speaker at yesterday’s session ‘Is cardiac rehabilitation still a must in the 21st century?’, thinks there most definitely is. “Meta-analyses1 have shown that rehabilitation can produce similar reductions in morbidity and mortality as achieved with classical drug treatment, such as aspirin and statins. Rehabilitation programmes also teach patients how to adopt a new way of life, which is important given that about 80% of all cardiovascular disease is related to unhealthy lifestyles. So a combination of cardiac rehabilitation and pharmacotherapy is the best way to reduce the risk of recurrent events.” Despite the evidence in favour of cardiac rehabilitation, it remains a much-neglected approach.

“Only 20–50% of patients eligible for cardiac rehabilitation programmes are referred for them.”

“If we saw such a low level of prescribing for secondary prevention drugs, there would be an outcry,” says Prof. Dendale. “One of the problems is that the evidence relies on meta-analyses rather than large randomised trials. Another issue is that the level of reimbursement varies between countries, with some offering no reimbursement at all. Policy changes are needed if patient access to cardiac rehabilitation programmes is to be increased.”

In addition, the long-term benefits of cardiac rehabilitation may be reduced by a lack of adherence. “In the initial stages after an event, patient adherence to classical programme recommendations is good, but in time, many revert to their original, unhealthy lifestyles. This suggests that the standard programme approach needs to be improved.”

Prof. Dendale’s group conducted a study involving a classical 3-month programme with or without an additional 6-month internet-based, patient-tailored telerehabilitation programme.2 “Compared with the classical programme, the telerehabilitation programme led to larger improvements in fitness and in health-related quality of life. These types of programmes may also have greater cost-effectiveness.” He concludes, “Mobile health may be one way of making cardiac rehabilitation programmes both more effective and more widely available.”

 

Don’t miss!

Cardiac rehabilitation: is mobile health the way to go?
Today, 08:30 – 10:00; Digital Health Stage 1 – Digital Health Area

 

Click here to read other scientific highlights in the ESC Congress news.

Download the Monday Edition in PDF format.

Access all the resources from congress presentations on ESC 365.

Follow the congress live!

Notes to editor

About the European Society of Cardiology

The European Society of Cardiology brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2019

ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2019 takes place 31 August to 4 September at the Paris Expo Porte de Versailles, Paris - France. Explore the scientific programme